Global Health Limited Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Global Health Limited, known for its Medanta brand, is navigating a significant expansion phase as it balances rapid bed capacity growth with the operational integration of new facilities like Noida. Investors will be focused on the margin trajectory as the company scales its footprint and the impact of rising employee costs on overall profitability.

Global Health Limited Q4 Results Date and Time

The company has scheduled its board meeting for May 14, 2026, to consider the audited financial results for the quarter and year ended March 31, 2026.

What to expect from Global Health Limited's Q4 FY26 results

In its most recently reported quarter, Global Health Limited posted revenue of Rs 1,121 Crores, PAT of Rs 95 Crores, and an EBITDA margin of 21.8%. The company is currently managing a significant expansion pipeline, having increased its total bed count to 3,579 as of December 31, 2025, which contributed to a 59% occupancy rate for the quarter. Management has guided for 5%-7% annual ARPOB growth over the next 2-3 years, while maintaining a focus on integrating new facilities like the 328-bed Noida hospital. The upcoming call will likely address the impact of a 36.3% YoY increase in employee benefits expense and the progress of new projects including the 400-bed Varanasi hospital and the Rs 322 Crore medical college.

Key Things To Watch

Performance vs Guidance Tracking

• ARPOB Growth — 5%-7% annually — Q3 FY26 achieved 9.9% YoY
• Noida Ramp-up — Losses near peak in Q3 — update on trajectory toward breakeven
• Occupancy Rates — 59% in Q3 FY26 — watch for stabilization post-expansion
• Developing Hospital Margins — 31.7% in Q3 FY26 — trend monitoring

Strategic Expansion Updates

• Noida facility — Full 550-bed capacity build-out timeline
• South Delhi & Pitampura — Commissioning timeline updates
• Indore Cancer Care acquisition — Integration progress ahead of September 30, 2026 long-stop date

Financial Performance Indicators

• EBITDA margin — Watch for Noida facility improvement from the 21.8% consolidated level
• Capital allocation — FY27 capex guidance below Rs 500 crores — confirm spending priorities
• International patient revenue — Sustainability of the 30% YoY growth seen in Q3

Risks and headwinds to monitor

• Labour cost inflation — Employee benefits expense increased 36.3% YoY
• Talent retention — Update on senior doctor attrition and recruitment pipeline
• CGHS rate revision — Any updates on financial impact assessment